Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH 2017 | The future of leukemia treatment in the elderly

John DiPersio • 5 Oct 2017
ESH 2017
Leukemia

An advanced age can limit treatment options when tackling leukemia. Speaking from the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH), Prof. John DiPersio, MD, PhD of Washington University School of Medicine, Washington, WA discusses treatment options for patients with leukemia who are over the age of 60, and the future applications of chemotherapy and bispecifics in this group.

More from John DiPersio

4:02
Identifying the optimal toxic payloads for antibody-based SCT conditioning using SAv-drug conjugates
John DiPersio • 21 Feb 2023
5:08
LBA: CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT
John DiPersio • 21 Feb 2023
4:13
ALL highlights: tisa-cel reinfusion in B-ALL & targeting CD5 and CD7 with CAR-Ts in T-ALL
John DiPersio • 21 Feb 2023
4:19
Advantages & concerns associated with the use of ADC-based conditioning in SCT recipients
John DiPersio • 21 Feb 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals